RU95110766A - Способ получения сложных эфиров баккатина-iii и 10-дезацетил-баккатина-iii, активированные кислоты и их производные - Google Patents

Способ получения сложных эфиров баккатина-iii и 10-дезацетил-баккатина-iii, активированные кислоты и их производные

Info

Publication number
RU95110766A
RU95110766A RU95110766/04A RU95110766A RU95110766A RU 95110766 A RU95110766 A RU 95110766A RU 95110766/04 A RU95110766/04 A RU 95110766/04A RU 95110766 A RU95110766 A RU 95110766A RU 95110766 A RU95110766 A RU 95110766A
Authority
RU
Russia
Prior art keywords
iii
baccatine
ris
radical
desacetyl
Prior art date
Application number
RU95110766/04A
Other languages
English (en)
Other versions
RU2123493C1 (ru
Inventor
Дени Жан-Ноэль
Be]
Грин Андрев
Мас Жан-Манюель
Us]
Fr]
Original Assignee
Рон-Пуленк Роре С.А. (FR)
Рон-Пуленк Роре С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Рон-Пуленк Роре С.А. (FR), Рон-Пуленк Роре С.А. filed Critical Рон-Пуленк Роре С.А. (FR)
Publication of RU95110766A publication Critical patent/RU95110766A/ru
Application granted granted Critical
Publication of RU2123493C1 publication Critical patent/RU2123493C1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epoxy Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)

Abstract

Предложен способ получения сложных эфиров баккатина-III или 10-дезацетил-баккатина-III формулы I путем этерификации до сложного эфира защищенного баккатина-III или 10-дезацетил-баккатина-III формулы II с помощью активированной кислоты формулы III. Указанные формулы приведены в описании изобретения. Сложные эфиры формулы I пригодны для получения производных таксана, обладающих замечательными антилейкемическими и противоопухолевыми свойствами.

Claims (1)

  1. Предложен способ получения сложных эфиров баккатина-III или 10-дезацетил-баккатина-III формулы I путем этерификации до сложного эфира защищенного баккатина-III или 10-дезацетил-баккатина-III формулы II с помощью активированной кислоты формулы III. Указанные формулы приведены в описании изобретения. Сложные эфиры формулы I пригодны для получения производных таксана, обладающих замечательными антилейкемическими и противоопухолевыми свойствами.
RU95110766A 1992-10-05 1993-10-04 Способ получения сложных эфиров баккатина-iii и 10-дезацетил-баккатина-iii, активированные кислоты и их производные RU2123493C1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9211739 1992-10-05
FR9211739A FR2696464B1 (fr) 1992-10-05 1992-10-05 Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.

Publications (2)

Publication Number Publication Date
RU95110766A true RU95110766A (ru) 1996-12-27
RU2123493C1 RU2123493C1 (ru) 1998-12-20

Family

ID=9434116

Family Applications (1)

Application Number Title Priority Date Filing Date
RU95110766A RU2123493C1 (ru) 1992-10-05 1993-10-04 Способ получения сложных эфиров баккатина-iii и 10-дезацетил-баккатина-iii, активированные кислоты и их производные

Country Status (24)

Country Link
US (2) US5717103A (ru)
EP (1) EP0663905B1 (ru)
JP (1) JP3064419B2 (ru)
KR (1) KR100290663B1 (ru)
AT (1) ATE147734T1 (ru)
AU (1) AU689446B2 (ru)
CA (1) CA2146372C (ru)
CZ (1) CZ284818B6 (ru)
DE (1) DE69307526T2 (ru)
DK (1) DK0663905T3 (ru)
ES (1) ES2096328T3 (ru)
FI (1) FI115909B (ru)
FR (1) FR2696464B1 (ru)
GR (1) GR3022286T3 (ru)
HU (1) HU225973B1 (ru)
MX (1) MX9305764A (ru)
NO (1) NO313141B1 (ru)
NZ (1) NZ256443A (ru)
PL (1) PL178090B1 (ru)
RU (1) RU2123493C1 (ru)
SK (1) SK281035B6 (ru)
TW (1) TW372234B (ru)
WO (1) WO1994007876A1 (ru)
ZA (1) ZA937316B (ru)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794523B2 (en) 1991-09-23 2004-09-21 Florida State University Taxanes having t-butoxycarbonyl substituted side-chains and pharmaceutical compositions containing them
FR2697522B1 (fr) * 1992-10-30 1994-11-25 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2698361B1 (fr) * 1992-11-20 1995-01-13 Rhone Poulenc Rorer Sa Procédé de préparation d'un acide oxazolidine-1,3 carboxylique-5.
MX9307777A (es) 1992-12-15 1994-07-29 Upjohn Co 7-HALO-Y 7ß, 8ß-METANO-TAXOLES, USO ANTINEOPLASTICO Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN.
ATE249448T1 (de) * 1993-06-11 2003-09-15 Upjohn Co Delta 6,7-taxol derivate antineoplastische verbindungen und diese enthaltende pharmazeutische zusammenstellungen
DE69435141D1 (de) 1993-07-19 2008-10-30 Angiotech Pharm Inc Anti-angiogene Mittel und Verfahren zu deren Verwendung
US5981537A (en) * 1993-11-12 1999-11-09 Pharmacia & Upjohn Company Pyrimidine-thioalkyl and alkylether compounds
IL127597A (en) * 1994-01-28 2003-07-31 Upjohn Co Iso-taxol analogs
AU716005B2 (en) 1995-06-07 2000-02-17 Cook Medical Technologies Llc Implantable medical device
PL329637A1 (en) * 1996-05-08 1999-04-12 Upjohn Co Taxol obtained method
US6150537A (en) 1997-12-12 2000-11-21 Emory University Methods for the esterification of alcohols and compounds useful therefor as potential anticancer agents
WO2002085337A1 (en) * 2001-04-20 2002-10-31 The University Of British Columbia Micellar drug delivery systems for hydrophobic drugs
JP4502338B2 (ja) * 1999-09-17 2010-07-14 株式会社横浜国際バイオ研究所 タキソイド化合物の製造法
EP2289549A3 (en) 1999-10-01 2011-06-15 Immunogen, Inc. Immunoconjugates for treating cancer
CA2307393A1 (en) 2000-05-01 2001-11-01 The University Of British Columbia Ginsenoside chemotherapy
HUP0302599A3 (en) 2000-09-22 2005-05-30 Bristol Myers Squibb Co Method for reducing toxicity of combined chemotherapic compositions
US20030157170A1 (en) * 2001-03-13 2003-08-21 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
CA2440935A1 (en) 2001-03-13 2002-09-19 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
EP2390262A1 (en) 2003-05-16 2011-11-30 Intermune, Inc. Synthetic chemokine receptor ligands and methods of use thereof
US8003122B2 (en) 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US7846940B2 (en) 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
US7989490B2 (en) 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
US8691780B2 (en) 2005-02-17 2014-04-08 The Board Of Trustees Of The Leland Stanford Junior University Txr1 and enhanced taxane sensitivity based on the modulation of a pathway mediated thereby
CA2922029C (en) 2006-03-22 2017-11-28 Medigene Ag A combination of a cationic liposomal preparation comprising an antimitotic agent and a non-liposomal preparation comprising an antimitotic agent
ATE519511T1 (de) 2006-06-30 2011-08-15 Cook Inc Verfahren zur herstellung und modifizierung von taxan-beschichtungen für implantierbare medizinische vorrichtungen
US8420110B2 (en) 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
US8409601B2 (en) 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
US8273404B2 (en) 2008-05-19 2012-09-25 Cordis Corporation Extraction of solvents from drug containing polymer reservoirs
ES2530462T3 (es) 2008-05-22 2015-03-03 Galera Therapeutics Llc Combinación terapia antitumoral
CN102046647A (zh) 2008-06-06 2011-05-04 哈博生物科学公司 制备17-炔基-7-羟基甾族化合物和相关化合物的方法
EP2310507A4 (en) 2008-07-08 2013-03-20 David Gladstone Inst METHODS AND COMPOSITIONS FOR MODULATING ANGIOGENESIS
US8642063B2 (en) 2008-08-22 2014-02-04 Cook Medical Technologies Llc Implantable medical device coatings with biodegradable elastomer and releasable taxane agent
PL388144A1 (pl) 2009-05-29 2010-12-06 Przedsiębiorstwo Produkcyjno-Wdrożeniowe Ifotam Spółka Z Ograniczoną Odpowiedzialnością Solwaty (2R,3S)-3-tert-butoksykarbonylamino-2-hydroksy-3-fenylopropionianu 4-acetoksy-2α-benzoiloksy -5β,20-epoksy-1,7β,10β-trihydroksy-9-okso-taks-11-en-13α-ylu, sposób ich otrzymywania i zastosowanie
US20120302954A1 (en) 2011-05-25 2012-11-29 Zhao Jonathon Z Expandable devices coated with a paclitaxel composition
US20120303115A1 (en) 2011-05-25 2012-11-29 Dadino Ronald C Expandable devices coated with a rapamycin composition
US9956385B2 (en) 2012-06-28 2018-05-01 The Spectranetics Corporation Post-processing of a medical device to control morphology and mechanical properties
EP3539563A1 (en) 2012-07-19 2019-09-18 Redwood Bioscience, Inc. Antibody specific for cd22 and methods of use thereof
EP2916835A4 (en) 2012-11-12 2016-07-27 Redwood Bioscience Inc COMPOUNDS AND METHOD FOR PRODUCING A CONJUGATE
PL2956175T3 (pl) 2013-02-15 2018-05-30 The Regents Of The University Of California Chimeryczny receptor antygenowy i sposoby jego zastosowania
EP2970124B1 (en) 2013-03-14 2019-05-22 The Board of Trustees of the Leland Stanford Junior University Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
WO2015081282A1 (en) 2013-11-27 2015-06-04 Redwood Bioscience, Inc. Hydrazinyl-pyrrolo compounds and methods for producing a conjugate
EP3107899B1 (en) 2014-02-19 2020-08-12 Aviv Therapeutics, Inc. Mitochondrial aldehyde dehydrogenase 2 (aldh2) binding polycyclic amides and their use for the treatment of cancer
JP6083815B2 (ja) * 2014-03-07 2017-02-22 立川ブラインド工業株式会社 タッセル
AU2016326747A1 (en) 2015-09-25 2018-03-01 Zy Therapeutics Inc. Drug formulation based on particulates comprising polysaccharide-vitamin conjugate
WO2017083637A1 (en) 2015-11-12 2017-05-18 The Board Of Trustees Of The Leland Stanford Junior University Cell-penetrating, guanidinium-rich oligophosphotriesters for drug and probe delivery
TWI760319B (zh) 2015-12-30 2022-04-11 杏國新藥股份有限公司 乳癌治療
CN109071634A (zh) 2016-04-26 2018-12-21 R.P.谢勒技术有限责任公司 抗体偶联物及其制备和使用方法
EP3463308B1 (en) 2016-06-01 2021-12-01 Servier IP UK Limited Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
TW201825087A (zh) 2017-01-05 2018-07-16 杏國新藥股份有限公司 胰臟癌治療
AU2018211081A1 (en) 2017-01-18 2019-07-18 Bioatla, Inc. Chimeric antigen receptors against Axl or Ror2 and methods of use thereof
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
CA3090129A1 (en) 2018-01-31 2019-08-08 Galera Labs, Llc Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
US11660266B2 (en) 2018-04-11 2023-05-30 Ohio State Innovation Foundation Methods and compositions for sustained release microparticles for ocular drug delivery
EP3823674A4 (en) 2018-07-18 2022-12-28 Manzanita Pharmaceuticals, Inc. CONJUGATES FOR DELIVERING AN ANTI-CANCER AGENT TO NERVE CELLS, METHODS OF USE AND METHODS OF PRODUCTION THEREOF
US11529402B2 (en) 2019-01-14 2022-12-20 Ignite Immunotherapy, Inc. Recombinant vaccinia virus and methods of use thereof
US11685904B2 (en) 2019-02-14 2023-06-27 Ignite Immunotherapy, Inc. Recombinant vaccinia virus and methods of use thereof
CN113692413A (zh) 2019-04-02 2021-11-23 肯乔克蒂生物技术股份有限公司 外排泵-癌症抗原多特异性抗体以及与其相关的组合物、试剂、试剂盒和方法
CA3163805A1 (en) 2019-12-12 2021-06-17 Ignite Immunotherapy, Inc. Variant oncolytic vaccinia virus and methods of use thereof
JP2023512196A (ja) 2020-01-29 2023-03-24 ケンジョッケティ バイオテクノロジー，インク． 抗ｍｄｒ１抗体およびその使用
AU2021283080A1 (en) 2020-06-04 2022-12-15 Kenjockety Biotechnology, Inc. ABCG2 efflux pump-cancer antigen multi-specific antibodies and compositions, reagents, kits and methods related thereto
WO2021247426A1 (en) 2020-06-04 2021-12-09 Kenjockety Biotechnology, Inc. Anti-abcg2 antibodies and uses thereof
BR112023000650A2 (pt) 2020-07-14 2023-01-31 Pfizer Vírus vaccinia recombinante
CN116490522A (zh) 2020-09-02 2023-07-25 肯乔克蒂生物技术股份有限公司 抗abcc1抗体及其应用
AU2021380659A1 (en) 2020-11-13 2023-06-01 Kenjockety Biotechnology, Inc. Anti-mrp4 (encoded by abcc4 gene) antibodies and uses thereof
WO2023114658A1 (en) 2021-12-13 2023-06-22 Kenjockety Biotechnology, Inc. Anti-abcb1 antibodies
WO2023159220A1 (en) 2022-02-18 2023-08-24 Kenjockety Biotechnology, Inc. Anti-cd47 antibodies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US34277A (en) * 1862-01-28 Improvement in lamps
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
FR2629818B1 (fr) * 1988-04-06 1990-11-16 Centre Nat Rech Scient Procede de preparation du taxol
USRE34277E (en) * 1988-04-06 1993-06-08 Centre National De La Recherche Scientifique Process for preparing taxol
MX9102128A (es) * 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
FR2696458B1 (fr) * 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2696460B1 (fr) * 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.

Also Published As

Publication number Publication date
NO951200D0 (no) 1995-03-29
FR2696464A1 (fr) 1994-04-08
CA2146372C (fr) 2003-09-09
DE69307526T2 (de) 1997-05-22
ES2096328T3 (es) 1997-03-01
HU225973B1 (en) 2008-02-28
CZ83995A3 (en) 1995-09-13
KR950703545A (ko) 1995-09-20
CA2146372A1 (fr) 1994-04-14
FI951593A0 (fi) 1995-04-04
AU5114893A (en) 1994-04-26
PL308239A1 (en) 1995-07-24
US5717103A (en) 1998-02-10
TW372234B (en) 1999-10-21
ATE147734T1 (de) 1997-02-15
JP3064419B2 (ja) 2000-07-12
DE69307526D1 (de) 1997-02-27
FI115909B (fi) 2005-08-15
NO951200L (no) 1995-03-29
DK0663905T3 (da) 1997-02-03
RU2123493C1 (ru) 1998-12-20
US5977375A (en) 1999-11-02
NO313141B1 (no) 2002-08-19
FR2696464B1 (fr) 1994-11-10
CZ284818B6 (cs) 1999-03-17
FI951593A (fi) 1995-04-04
HUT72616A (en) 1996-05-28
AU689446B2 (en) 1998-04-02
JPH08501787A (ja) 1996-02-27
GR3022286T3 (en) 1997-04-30
KR100290663B1 (ko) 2001-09-17
NZ256443A (en) 1996-07-26
MX9305764A (es) 1995-01-31
SK43895A3 (en) 1995-08-09
WO1994007876A1 (fr) 1994-04-14
EP0663905B1 (fr) 1997-01-15
HU9500970D0 (en) 1995-06-28
PL178090B1 (pl) 2000-02-29
EP0663905A1 (fr) 1995-07-26
SK281035B6 (sk) 2000-11-07
ZA937316B (en) 1994-04-22

Similar Documents

Publication Publication Date Title
RU95110766A (ru) Способ получения сложных эфиров баккатина-iii и 10-дезацетил-баккатина-iii, активированные кислоты и их производные
CN1073105C (zh) 具有抗肿瘤活性的半合成紫杉烷
RU95110682A (ru) Способ получения производных таксана, исходные и промежуточные продукты для его получения
NO951318L (no) 25-karboxylsyrederivater i vitamin D-serien, fremgangsmåte for fremstilling av disse, mellomprodukter for fremgangsmåten, farmasöytiske preparater inneholdende disse derivater og deres anvendelse ved fremstilling av medisiner
RU94040356A (ru) Способ получения производных таксана
RU95111381A (ru) Способ получения производных таксана и промежуточные соединения синтеза
ATE27701T1 (de) 2-carbamimidoyl-6-substituierte-1-carbadethiape - 2-em-3-carbonsaeure, verfahren zur herstellung und sie enthaltendes antibiotisches arzneipraeparat.
RU94045799A (ru) СПОСОБ ПОЛУЧЕНИЯ β-ФЕНИЛИЗОСЕРИНА И ЕГО АНАЛОГОВ, СПОСОБ ПОЛУЧЕНИЯ ПРОИЗВОДНЫХ ТАКСАНА И ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ СИНТЕЗА
ATE37360T1 (de) Ester von imidazolaethanol.
KR890011859A (ko) 3,5-디하이드록시 카복실산 및 이의 유도체, 이의 제조방법, 약물로서의 이의 용도, 약제학적 생성물 및 중간체
GB1317781A (en) D-glucofuranose compounds and process for preparing them
ATE82569T1 (de) Herstellung von chinolincarbonsaeuren.
DE69228541D1 (de) Chinasäurederivate und Verfahren zur Herstellung von Chinasäurederivaten
KR840005116A (ko) 옥사졸초산 유도체의 제조방법
RU94041682A (ru) Способ получения производных таксана
DE3280255D1 (de) Herstellung von substituierten gamma-butyrolactonen, verwendbar als zwischenprodukte zur herstellung von fungiziden imidazolen und triazolen.
RU95113420A (ru) Способы получения 1,3-оксазолидин-5-карбоновой кислоты
RU95111377A (ru) Производное бета -фенилизосерина, способ его стереоселективного получения, исходное соединение для его получения, способ получения производных таксана, получаемые при этом продукты
GB1075494A (en) Anthranilic acid compounds and methods for their production
GB1259947A (en) A process for the manufacture of epoxy carboxylyic acids and derivatives thereof
KR910004652A (ko) 5-α-환원 효소억제제로서의 3-치환된 니트로-스테로이드 유도체
GB1469416A (en) Process for the preparation of quinoline derivatives
SE7510787L (sv) Nya kvevehaltiga, polycykliska foreningar, salter derav och deras optiska antipoder, jemte sett for deras framstellning
GB1516452A (en) Process for the manufacture of polycarboxylic acid polyglycidyl esters
ATE61329T1 (de) Verfahren zur herstellung von rooperol, hypoxosid und deren derivaten.